Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

The lawsuit said the union’s health plan allowed coverage of Xenical to treat obesity but not newer products such as Wegovy ...

More than 1% of U.S. children between the ages of 2 and 18 had “extremely severe obesity” in 2023 — a 250% increase from 2008 ...

Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

Scientists found that obesity may exist in 11 biological forms, each linked to different genes and body functions.

Significant periods of weight regain were observed at eight, 12, and 20 weeks after stopping the anti-obesity medications. The analysis revealed that the weight rebound typically continued for an ...

It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...

Doctors around the world have been hailing "miracle" medications that make weight loss far easier, but new research suggests ...